New Content  edit

Live CME/CNE/CPE Certified Webinar
Presented by Expert Faculty

Live CME/CNE/CPE Certified Webinar
(0.5 Credit Hours)
Presented by Expert Faculty

FGF23 Mediated Hypophosphatemia - Common Symptoms for an Uncommon Disease: Tumor-Induced Osteomalacia (TIO)

BROADCAST SCHEDULE

No events currently scheduled.

Webinar Overview

TIO, also known as oncogenic osteomalacia, is a rare paraneoplastic syndrome caused by unregulated production of FGF23 by a tumor. Despite the biochemical hallmarks (e.g., elevated FGF23), the diagnosis of TIO is often elusive due to lack of knowledge or failure to investigate serum phosphate and FGF23 levels, and the nonspecific symptoms of TIO (i.e.,muscle weakness, bone pain, and pathologic fractures). This free certified CME/CE webinar features expert faculty from the National Institutes of Health who review case-based presentations of TIO symptoms.

PLUS: Live Q&A panel discussion with faculty at the end of each broadcast

Faculty

Michael Collins, MD

Senior Investigator
Chief, Skeletal Disorders and Mineral Homeostasis Section
National Institute of Dental and Craniofacial Research
Director, Career Development and Research Training
NIH Interinstitute Endocrine Training Program
National Institutes of Health
Bethesda, MD

Iris Hartley, MD

Clinical Investigator, Skeletal Disorders and
Mineral Homeostasis Section
National Institute of Dental and Craniofacial Research
Faculty, Inter-institute Endocrine Training Program
National Institutes of Health
Bethesda, MD

Learning Objectives

  • Discuss the roles of excess FGF23 in the pathogenesis and sequalae of TIO
  • Describe common presenting clinical signs and symptoms and biochemical markers associated with TIO and should initiate a diagnostic workup
  • Review available clinical data for burosumab treatment in patients with TIO associated with PMTs

Target Audience

This program is designed to meet the educational needs of physicians, registered nurses, pharmacists and other healthcare professionals involved in the care of patients with TIO.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and TotalCME. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-20-2381-L01-P
Type of Activity: Application
Note: Pharmacists must complete all episodes in this activity to claim credit.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.
Note: Nurses must complete all episodes in this activity to claim credit.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Fee Information
There is no fee for this educational activity.

PIM
TotalCME

This activity is supported by an independent educational grant from Ultragenyx Pharmaceutical Inc.
Jointly provided by Postgraduate Institute for Medicine and TotalCME, Inc.